14-day Premium Trial Subscription Sign Up For FreeGet Free

ABIO Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -11.40% during the next 3 months and, with a 90% probability hold a price between $2.27 and $2.78 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-30 $2.55 $2.84 $3.13
2021-10-01 $2.55 $2.84 $3.13
2021-10-04 $2.54 $2.83 $3.12
2021-10-05 $2.53 $2.82 $3.12
2021-10-06 $2.53 $2.82 $3.11
2021-10-07 $2.52 $2.81 $3.10
2021-10-08 $2.51 $2.81 $3.10
2021-10-11 $2.51 $2.80 $3.09
2021-10-12 $2.50 $2.79 $3.08
2021-10-13 $2.50 $2.79 $3.08
2021-10-14 $2.49 $2.78 $3.07
2021-10-15 $2.48 $2.77 $3.06
2021-10-18 $2.48 $2.77 $3.06
2021-10-19 $2.47 $2.76 $3.05
2021-10-20 $2.46 $2.75 $3.04
2021-10-21 $2.46 $2.75 $3.04
2021-10-22 $2.45 $2.74 $3.03
2021-10-25 $2.44 $2.73 $3.03
2021-10-26 $2.44 $2.73 $3.02
2021-10-27 $2.43 $2.72 $3.01
2021-10-28 $2.42 $2.72 $3.01
2021-10-29 $2.42 $2.71 $3.00
2021-11-01 $2.41 $2.70 $2.99
2021-11-02 $2.41 $2.70 $2.99
2021-11-03 $2.40 $2.69 $2.98
2021-11-04 $2.39 $2.68 $2.97
2021-11-05 $2.39 $2.68 $2.97
2021-11-08 $2.38 $2.67 $2.96
2021-11-09 $2.37 $2.66 $2.95
2021-11-10 $2.37 $2.66 $2.95

About ARCA biopharma

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nem... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT